Drug Trial Radar · NCT02927314
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
Last checked: Nov 19, 2026Latest source record: Mar 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Nov 27, 2017
Primary completion
Mar 1, 2020
Study completion Mar 1, 2020
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.
Conditions
- Non-alcoholic Steatohepatitis (NASH)
Interventions
CF102Drug
orally q12h
PlaceboDrug
orally q12h
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levelsTime frame: 12 weeks
- Efficacy of CF102 as determined by change in magnetic resonance imaging-determined hepatic steatosisTime frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Can-Fite Investigational Site #318
Jerusalem, Israel
Can-Fite Investigational Site #319
Nazareth, Israel
Can-Fite Investigational Site #311
Petah Tikva, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.